|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KAT2B |
Gene summary for KAT2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KAT2B | Gene ID | 8850 |
| Gene name | lysine acetyltransferase 2B | |
| Gene Alias | CAF | |
| Cytomap | 3p24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | Q92831 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8850 | KAT2B | 048752_1579-all-cells | Human | Prostate | BPH | 4.30e-04 | 2.05e-01 | 0.1008 |
| 8850 | KAT2B | 052095_1628-all-cells | Human | Prostate | BPH | 9.24e-07 | 2.72e-01 | 0.1032 |
| 8850 | KAT2B | 052099_1652-all-cells | Human | Prostate | BPH | 1.39e-08 | 2.71e-01 | 0.1038 |
| 8850 | KAT2B | Dong_P3 | Human | Prostate | Tumor | 6.82e-09 | 1.50e-01 | 0.0278 |
| 8850 | KAT2B | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 6.37e-12 | 5.69e-01 | 0.1633 |
| 8850 | KAT2B | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.30e-11 | 5.42e-01 | 0.1608 |
| 8850 | KAT2B | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 3.01e-05 | 4.30e-01 | 0.1604 |
| 8850 | KAT2B | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 6.94e-07 | 4.54e-01 | 0.1621 |
| 8850 | KAT2B | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 4.81e-05 | 6.29e-01 | 0.1619 |
| 8850 | KAT2B | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 1.92e-02 | 5.54e-01 | 0.159 |
| 8850 | KAT2B | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 3.18e-03 | 3.56e-01 | 0.1602 |
| 8850 | KAT2B | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 4.56e-05 | 5.68e-01 | 0.1608 |
| 8850 | KAT2B | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.51e-05 | 5.66e-01 | 0.1622 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002261318 | Prostate | BPH | ribonucleoprotein complex biogenesis | 150/3107 | 463/18723 | 2.18e-17 | 5.62e-15 | 150 |
| GO:004851110 | Prostate | BPH | rhythmic process | 96/3107 | 298/18723 | 1.88e-11 | 1.31e-09 | 96 |
| GO:004593618 | Prostate | BPH | negative regulation of phosphate metabolic process | 124/3107 | 441/18723 | 5.95e-10 | 2.90e-08 | 124 |
| GO:001056318 | Prostate | BPH | negative regulation of phosphorus metabolic process | 124/3107 | 442/18723 | 6.94e-10 | 3.25e-08 | 124 |
| GO:004232617 | Prostate | BPH | negative regulation of phosphorylation | 110/3107 | 385/18723 | 2.08e-09 | 8.35e-08 | 110 |
| GO:190165310 | Prostate | BPH | cellular response to peptide | 104/3107 | 359/18723 | 2.51e-09 | 1.00e-07 | 104 |
| GO:004225418 | Prostate | BPH | ribosome biogenesis | 90/3107 | 299/18723 | 3.82e-09 | 1.44e-07 | 90 |
| GO:000193317 | Prostate | BPH | negative regulation of protein phosphorylation | 97/3107 | 342/18723 | 2.74e-08 | 8.11e-07 | 97 |
| GO:00165706 | Prostate | BPH | histone modification | 120/3107 | 463/18723 | 1.73e-07 | 3.89e-06 | 120 |
| GO:005134818 | Prostate | BPH | negative regulation of transferase activity | 78/3107 | 268/18723 | 1.94e-07 | 4.29e-06 | 78 |
| GO:004343417 | Prostate | BPH | response to peptide hormone | 109/3107 | 414/18723 | 2.73e-07 | 5.91e-06 | 109 |
| GO:00719009 | Prostate | BPH | regulation of protein serine/threonine kinase activity | 97/3107 | 359/18723 | 3.42e-07 | 7.23e-06 | 97 |
| GO:00713759 | Prostate | BPH | cellular response to peptide hormone stimulus | 82/3107 | 290/18723 | 3.65e-07 | 7.65e-06 | 82 |
| GO:003286910 | Prostate | BPH | cellular response to insulin stimulus | 61/3107 | 203/18723 | 1.26e-06 | 2.20e-05 | 61 |
| GO:00516049 | Prostate | BPH | protein maturation | 80/3107 | 294/18723 | 2.64e-06 | 4.23e-05 | 80 |
| GO:000646916 | Prostate | BPH | negative regulation of protein kinase activity | 62/3107 | 212/18723 | 2.81e-06 | 4.45e-05 | 62 |
| GO:003286810 | Prostate | BPH | response to insulin | 73/3107 | 264/18723 | 3.80e-06 | 5.83e-05 | 73 |
| GO:003367315 | Prostate | BPH | negative regulation of kinase activity | 67/3107 | 237/18723 | 4.15e-06 | 6.25e-05 | 67 |
| GO:00182055 | Prostate | BPH | peptidyl-lysine modification | 96/3107 | 376/18723 | 5.70e-06 | 8.39e-05 | 96 |
| GO:19040292 | Prostate | BPH | regulation of cyclin-dependent protein kinase activity | 34/3107 | 98/18723 | 1.00e-05 | 1.39e-04 | 34 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516628 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
| hsa032504 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
| hsa0491924 | Prostate | BPH | Thyroid hormone signaling pathway | 39/1718 | 121/8465 | 1.27e-03 | 5.58e-03 | 3.45e-03 | 39 |
| hsa05166112 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
| hsa0325012 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
| hsa04919111 | Prostate | BPH | Thyroid hormone signaling pathway | 39/1718 | 121/8465 | 1.27e-03 | 5.58e-03 | 3.45e-03 | 39 |
| hsa0516629 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
| hsa0520323 | Prostate | Tumor | Viral carcinogenesis | 70/1791 | 204/8465 | 7.53e-06 | 6.56e-05 | 4.07e-05 | 70 |
| hsa0325021 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
| hsa0491925 | Prostate | Tumor | Thyroid hormone signaling pathway | 40/1791 | 121/8465 | 1.47e-03 | 6.26e-03 | 3.88e-03 | 40 |
| hsa043302 | Prostate | Tumor | Notch signaling pathway | 22/1791 | 62/8465 | 6.45e-03 | 2.16e-02 | 1.34e-02 | 22 |
| hsa0516637 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
| hsa0520333 | Prostate | Tumor | Viral carcinogenesis | 70/1791 | 204/8465 | 7.53e-06 | 6.56e-05 | 4.07e-05 | 70 |
| hsa032503 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
| hsa0491934 | Prostate | Tumor | Thyroid hormone signaling pathway | 40/1791 | 121/8465 | 1.47e-03 | 6.26e-03 | 3.88e-03 | 40 |
| hsa043303 | Prostate | Tumor | Notch signaling pathway | 22/1791 | 62/8465 | 6.45e-03 | 2.16e-02 | 1.34e-02 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KAT2B | SNV | Missense_Mutation | rs774973502 | c.1658N>A | p.Arg553His | p.R553H | Q92831 | protein_coding | deleterious(0.03) | possibly_damaging(0.543) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| KAT2B | SNV | Missense_Mutation | c.1083N>G | p.Asn361Lys | p.N361K | Q92831 | protein_coding | deleterious(0.01) | benign(0.211) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| KAT2B | SNV | Missense_Mutation | rs772124073 | c.1547N>G | p.Val516Gly | p.V516G | Q92831 | protein_coding | deleterious(0.03) | benign(0.095) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KAT2B | SNV | Missense_Mutation | rs773908616 | c.1607N>A | p.Arg536Gln | p.R536Q | Q92831 | protein_coding | tolerated(0.23) | benign(0.049) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| KAT2B | SNV | Missense_Mutation | rs772124073 | c.1547N>G | p.Val516Gly | p.V516G | Q92831 | protein_coding | deleterious(0.03) | benign(0.095) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| KAT2B | insertion | Nonsense_Mutation | novel | c.2459_2460insATGA | p.Phe820LeufsTer2 | p.F820Lfs*2 | Q92831 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| KAT2B | insertion | Frame_Shift_Ins | novel | c.2460_2461insCAAGGAAAACAGTTCTTAAATCTTAAGTTCA | p.Phe821GlnfsTer13 | p.F821Qfs*13 | Q92831 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| KAT2B | insertion | Frame_Shift_Ins | novel | c.2391_2392insA | p.Asn798LysfsTer9 | p.N798Kfs*9 | Q92831 | protein_coding | TCGA-GM-A2DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD | ||
| KAT2B | SNV | Missense_Mutation | c.1297N>C | p.Asp433His | p.D433H | Q92831 | protein_coding | deleterious(0.03) | benign(0.014) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| KAT2B | SNV | Missense_Mutation | novel | c.1789N>G | p.His597Asp | p.H597D | Q92831 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | amphetamine | AMPHETAMINE | ||
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | TRIAZOLAM | TRIAZOLAM | 22137933 | |
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | cannabinoids | NABIXIMOLS | ||
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | inhibitor | 178103578 | ||
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | opioids | |||
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | DIETHYL-2-DODECYLIDENEMALONATE | CHEMBL1797708 | 21292492 | |
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | cocaine | COCAINE | ||
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 | |
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | ANACARDIC ACID | 20655754 | ||
| 8850 | KAT2B | ENZYME, DRUGGABLE GENOME | inhibitor | 252166597 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |